Nurix Therapeutics announced the initiation of its pivotal DAYBreak Phase 2 clinical trial evaluating bexobrutideg for relapsed or refractory chronic…
Read More

Nurix Therapeutics announced the initiation of its pivotal DAYBreak Phase 2 clinical trial evaluating bexobrutideg for relapsed or refractory chronic…
Read More